drugset / Trial / NCT04733183

Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma

NCT04733183

Phase 2 Active not recruiting 98 enrolled Philogen S.p.A.
RandomizedParallel-groupOpen-labelTreatment

Summary

Open label, randomized, controlled phase II study preceded by a safety run-in part in subjects with advanced or metastatic soft-tissue sarcoma.

Timeline

Start
2020-08-28
Primary completion
2025-12
Completion
2025-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Dacarbazine Small molecule 850 mg/m2
Subject Dacarbazine Small molecule 1000 mg/m2
Subject Onfekafusp alfa Protein / enzyme biologic 13 ug/kg

Indications